|
84 Companies |
|
139 Products |
|
139 Products |
|
62 Mechanisms of Action |
|
7 Trials |
|
632 News |
|
| «12345678910111213...1314» |
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment closed: Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Aug 13, 2015
P1/2, N=225, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Recruiting --> Active, not recruiting
- Trial completion, Post-transplantation: Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies (clinicaltrials.gov) - Aug 12, 2015
P2, N=44, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Enrollment change, Trial primary completion date: Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant (clinicaltrials.gov) - Jul 10, 2015
P2, N=6, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=88 --> 6 | Trial primary completion date: Sep 2014 --> Dec 2011
- Trial primary completion date, Metastases: Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss (clinicaltrials.gov) - Jul 9, 2015
P1/2, N=63, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed | N=88 --> 6 | Trial primary completion date: Sep 2014 --> Dec 2011 Trial primary completion date: Nov 2004 --> Jul 2004
- | baclofen / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer (clinicaltrials.gov) - Jul 9, 2015
P3, N=211, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Nov 2004 --> Jul 2004 Active, not recruiting --> Completed | N=148 --> 211 | Trial primary completion date: Jan 2010 --> Apr 2009
- || denintuzumab mafodotin (SGN-CD19A) / Pfizer
Trial primary completion date: A Safety Study of SGN-CD19A for B-Cell Lymphoma (clinicaltrials.gov) - Jul 2, 2015
P1, N=175, Recruiting, Sponsor: Seattle Genetics, Inc.
Active, not recruiting --> Completed | N=148 --> 211 | Trial primary completion date: Jan 2010 --> Apr 2009 Trial primary completion date: May 2015 --> Sep 2015
- || fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Jun 30, 2015
P1/2, N=225, Recruiting, Sponsor: OHSU Knight Cancer Institute
Trial primary completion date: May 2015 --> Sep 2015 Trial primary completion date: Dec 2016 --> Mar 2015
- dasatinib / Generic mfg.
Trial completion, Surgery, Metastases: Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 26, 2015
P1, N=80, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2016 --> Mar 2015 Active, not recruiting --> Completed
- Imbruvica (ibrutinib) / AbbVie, J&J
Trial primary completion date: Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 11, 2015
P2, N=20, Recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Jun 2015 --> Jun 2016
- Zolinza (vorinostat) / Merck (MSD), alisertib (MLN8237) / Puma
Trial primary completion date, Combination therapy, Epigenetic controller: Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Jun 11, 2015
P1, N=60, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2015 --> Jun 2016 Trial primary completion date: Apr 2015 --> Dec 2015
- || Trial primary completion date, Metastases: AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma (clinicaltrials.gov) - Jun 11, 2015
P1, N=60, Active, not recruiting, Sponsor: Craig Hofmeister
Trial primary completion date: Apr 2015 --> Dec 2015 Trial primary completion date: Jun 2015 --> Dec 2015
- Trial withdrawal: Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers (clinicaltrials.gov) - Jun 11, 2015
P=N/A, N=0, Withdrawn, Sponsor: Rutgers, The State University of New Jersey
Trial primary completion date: Jun 2015 --> Dec 2015 Terminated --> Withdrawn
- dasatinib / Generic mfg.
Enrollment change, Surgery, Metastases: Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 3, 2015
P1, N=80, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Terminated --> Withdrawn N=42 --> 80
- Elitek (rasburicase) / Sanofi
Enrollment change, Trial termination: Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - May 29, 2015
P2, N=21, Terminated, Sponsor: Roswell Park Cancer Institute
N=42 --> 80 N=36 --> 21 | Recruiting --> Terminated; low accrual
- Enrollment open: Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies (clinicaltrials.gov) - May 20, 2015
P1, N=18, Recruiting, Sponsor: Robert Lowsky
N=36 --> 21 | Recruiting --> Terminated; low accrual Active, not recruiting --> Recruiting
- Elitek (rasburicase) / Sanofi
Trial completion: Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant (clinicaltrials.gov) - May 12, 2015
P=N/A, N=25, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Recruiting Recruiting --> Completed
- ||| Trial completion: Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients (clinicaltrials.gov) - May 7, 2015
P=N/A, N=483, Completed, Sponsor: Children's Oncology Group
Recruiting --> Completed Active, not recruiting --> Completed
- peripheral blood stem cell transplantation / National Cancer Institute
Enrollment change, Trial withdrawal, Gene therapy: Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma (clinicaltrials.gov) - May 7, 2015
P=N/A, N=0, Withdrawn, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed N=13 --> 0 | Not yet recruiting --> Withdrawn
- || Zolinza (vorinostat) / Merck (MSD), Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Phase classification, Trial primary completion date: Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - May 5, 2015
P2, N=66, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
N=13 --> 0 | Not yet recruiting --> Withdrawn Phase classification: P1/2 --> P2 | Trial primary completion date: Sep 2014 --> Aug 2015
- ||| Biomarker, Enrollment open: AALL12B3: Studying Biomarkers as a Diagnostic Tool in Samples From Younger Patients With B-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 5, 2015
P=N/A, N=70, Recruiting, Sponsor: Children's Oncology Group
Phase classification: P1/2 --> P2 | Trial primary completion date: Sep 2014 --> Aug 2015 Active, not recruiting --> Recruiting
- Monjuvi (tafasitamab-cxix) / Incyte
Enrollment change, Trial termination: Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL) (clinicaltrials.gov) - Apr 28, 2015
P2a, N=22, Terminated, Sponsor: MorphoSys AG
Active, not recruiting --> Recruiting N=30 --> 22 | Recruiting --> Terminated
- | LMB-2 / National Cancer Institute
Trial completion: LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma (clinicaltrials.gov) - Apr 28, 2015
P1, N=40, Completed, Sponsor: National Cancer Institute (NCI)
N=30 --> 22 | Recruiting --> Terminated Recruiting --> Completed
- | Trial completion: Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation (clinicaltrials.gov) - Apr 28, 2015
P=N/A, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Recruiting --> Completed
- | 7-Hydroxystaurosporine (UCN-01) / National Cancer Institute
Trial completion: UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma (clinicaltrials.gov) - Apr 28, 2015
P1, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma (clinicaltrials.gov) - Apr 28, 2015
P1, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | arsenic trioxide / Generic mfg.
Trial completion: Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma (clinicaltrials.gov) - Apr 27, 2015
P1, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Completed No longer recruiting --> Completed
- | alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion: Flavopiridol in Treating Patients With Refractory Cancer (clinicaltrials.gov) - Apr 27, 2015
P1, N=0, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Not yet recruiting --> Completed
- | Trial completion: Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Apr 27, 2015
P1, N=24, Completed, Sponsor: National Institute on Aging (NIA)
Not yet recruiting --> Completed Suspended --> Completed
- | LMB-2 / National Cancer Institute
Trial completion: Immunotoxin in Treating Patients With Leukemia or Lymphoma (clinicaltrials.gov) - Apr 27, 2015
P1, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed Not yet recruiting --> Completed
- Trial initiation date: Treg Cells for AGVHD in Non-myeloablative UCB Transplant (clinicaltrials.gov) - Apr 25, 2015
P2, N=18, Not yet recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Not yet recruiting --> Completed Initiation date: Apr 2014 --> Dec 2015
- methoxyamine (TRC102) / Tracon Pharma
Enrollment change: Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies (clinicaltrials.gov) - Apr 25, 2015
P1, N=20, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Initiation date: Apr 2014 --> Dec 2015 N=30 --> 20
- || Trial primary completion date: Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Apr 19, 2015
P=N/A, N=100, Active, not recruiting, Sponsor: Mayo Clinic
N=30 --> 20 Trial primary completion date: Dec 2014 --> Dec 2015
- Rituxan (rituximab) / Roche, Yervoy (ipilimumab) / BMS
Trial primary completion date, Combination therapy: Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (clinicaltrials.gov) - Apr 14, 2015
P1, N=38, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Apr 2015 --> Apr 2016
- alisertib (MLN8237) / Puma
Trial primary completion date: MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine (clinicaltrials.gov) - Apr 14, 2015
P1/2, N=43, Active, not recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Trial primary completion date: Apr 2015 --> Apr 2016 Trial primary completion date: Mar 2014 --> Feb 2015
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Apr 14, 2015
P2, N=47, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Mar 2014 --> Feb 2015 Trial primary completion date: Mar 2015 --> Sep 2015
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change, Trial termination, Trial primary completion date: Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant (clinicaltrials.gov) - Apr 13, 2015
P2, N=11, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Mar 2015 --> Sep 2015 N=28 --> 11 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Oct 2014; Replaced by another protocol
- Depocyte (liposomal cytarabine) / Mundipharma, Leadiant Biosci
Trial completion, Enrollment change, Trial primary completion date: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - Apr 3, 2015
P=N/A, N=2, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
N=28 --> 11 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Oct 2014; Replaced by another protocol Recruiting --> Completed | N=29 --> 2 | Trial primary completion date: Dec 2016 --> Jan 2015
- || Enrollment closed, IO biomarker: Prognostic Potential Cell Surface Markers CD47 / CD27 / CD8 and Pim-kinase in Patients With Hematologic Malignancies or Solid Tumors (clinicaltrials.gov) - Mar 27, 2015
P=N/A, N=150, Active, not recruiting, Sponsor: Cancer Centre of Monoclonal Therapy, LLC
Recruiting --> Completed | N=29 --> 2 | Trial primary completion date: Dec 2016 --> Jan 2015 Recruiting --> Active, not recruiting
- | Rituxan (rituximab) / Roche
Trial completion, Enrollment change, Trial primary completion date: Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 26, 2015
P1, N=15, Completed, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=24 --> 15 | Trial primary completion date: Dec 2012 --> Jan 2010
- sirolimus / Generic mfg.
Trial termination: Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 12, 2015
P1, N=10, Terminated, Sponsor: Children's Hospital of Philadelphia
Active, not recruiting --> Completed | N=24 --> 15 | Trial primary completion date: Dec 2012 --> Jan 2010 Suspended --> Terminated; Recruiting/enrolling participants halted prematurely but potentially will resume
- fludarabine IV / Generic mfg., mycophenolate mofetil / Generic mfg.
Trial primary completion date, Combination therapy, IO biomarker, Post-transplantation: Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (clinicaltrials.gov) - Mar 7, 2015
P=N/A, N=20, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Suspended --> Terminated; Recruiting/enrolling participants halted prematurely but potentially will resume Trial primary completion date: Dec 2014 --> Dec 2015
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed: Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma (clinicaltrials.gov) - Mar 7, 2015
P2, N=43, Active, not recruiting, Sponsor: University of Washington
Trial primary completion date: Dec 2014 --> Dec 2015 Completed --> Active, not recruiting
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Feb 19, 2015
P2, N=47, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Completed --> Active, not recruiting Trial primary completion date: Mar 2014 --> Mar 2015
- Rituxan (rituximab) / Roche
Trial completion: Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma (clinicaltrials.gov) - Feb 19, 2015
P1, N=10, Completed, Sponsor: University of California, San Francisco
Trial primary completion date: Mar 2014 --> Mar 2015 Active, not recruiting --> Completed
- Trial completion: A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies (clinicaltrials.gov) - Feb 11, 2015
P1, N=23, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Bexxar (iodine I 131 tositumomab) / GSK
Trial completion: Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 5, 2015
P2, N=25, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date: Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer (clinicaltrials.gov) - Feb 5, 2015
P1, N=40, Active, not recruiting, Sponsor: California Cancer Consortium
Active, not recruiting --> Completed Trial primary completion date: Dec 2013 --> Dec 2015
- busulfan / Generic mfg.
Enrollment closed, Trial primary completion date: Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant (clinicaltrials.gov) - Feb 2, 2015
P0, N=30, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Dec 2013 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jul 2015
- Enrollment closed, Enrollment change: Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies (clinicaltrials.gov) - Feb 2, 2015
P1, N=9, Active, not recruiting, Sponsor: Robert Lowsky
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jul 2015 Recruiting --> Active, not recruiting | N=18 --> 9
- alisertib (MLN8237) / Puma, Istodax (romidepsin) / Astellas, BMS
Trial primary completion date: Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas (clinicaltrials.gov) - Jan 20, 2015
P1, N=30, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=18 --> 9 Trial primary completion date: Dec 2014 --> Mar 2016